Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254774775> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4254774775 abstract "Abstract Purpose This study aimed to evaluate the potential of podoplanin (PDPN)-targeted alpharadiotherapy (RIT) for treating malignant mesothelioma. Methods A newly developed anti-PDPN antibody, NZ-16, and a previous anti-PDPN antibody, NZ-12, were assessed. The in vitro properties of radiolabeled antibodies were evaluated by cell binding and competitive inhibition assays using PDPN-expressing NCI-H226 (H226) mesothelioma cells. The biodistribution of 111 In-labeled antibodies was studied in tumorbearing mice. Tumor volumes and body weights of mice treated with 90 Y- and 225 Ac-labeled NZ-16 were measured for 56 days. The absorbed doses were estimated on the basis of the biodistribution data. Pathologic analysis of tumors and organs was conducted. Results The radiolabeled NZ-16 specifically bound to H226 cells with higher affinity than NZ12. The biodistribution studies showed higher tumor uptake of radiolabeled NZ-16 compared with NZ-12. RIT with 225 Ac-labeled NZ-16 (11.1 and 18.5 kBq) had a significantly higher antitumor effect than RIT with 90 Y-labeled NZ-16 (3.7 MBq; P < 0.01). 225 Ac-labeled NZ-16 induced more necrosis compared with 90 Y-labeled NZ-16, but the Ki-67 index and apoptosis rate were similar. The estimated absorbed doses were expected to be tolerable in mice. Temporary body weight loss occurred, but recovered within several days. No visible damage to major organs was detected. Conclusion The novel anti-PDPN antibody NZ-16 was a more effective RIT agent than NZ12. Radiolabeled NZ-16, especially 225 Ac-labeled NZ-16, markedly suppressed tumor growth and prolonged survival without inducing severe adverse effects. RIT with radiolabeled NZ-16 is a promising therapeutic option for malignant mesothelioma." @default.
- W4254774775 created "2022-05-12" @default.
- W4254774775 creator A5030574164 @default.
- W4254774775 creator A5031934157 @default.
- W4254774775 creator A5035001561 @default.
- W4254774775 creator A5037392716 @default.
- W4254774775 creator A5038612225 @default.
- W4254774775 creator A5052288586 @default.
- W4254774775 creator A5060119598 @default.
- W4254774775 creator A5067101373 @default.
- W4254774775 date "2021-07-12" @default.
- W4254774775 modified "2023-10-16" @default.
- W4254774775 title "Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with The Novel Antibody NZ-16 for Malignant Mesothelioma" @default.
- W4254774775 doi "https://doi.org/10.21203/rs.3.rs-691419/v1" @default.
- W4254774775 hasPublicationYear "2021" @default.
- W4254774775 type Work @default.
- W4254774775 citedByCount "1" @default.
- W4254774775 countsByYear W42547747752022 @default.
- W4254774775 crossrefType "posted-content" @default.
- W4254774775 hasAuthorship W4254774775A5030574164 @default.
- W4254774775 hasAuthorship W4254774775A5031934157 @default.
- W4254774775 hasAuthorship W4254774775A5035001561 @default.
- W4254774775 hasAuthorship W4254774775A5037392716 @default.
- W4254774775 hasAuthorship W4254774775A5038612225 @default.
- W4254774775 hasAuthorship W4254774775A5052288586 @default.
- W4254774775 hasAuthorship W4254774775A5060119598 @default.
- W4254774775 hasAuthorship W4254774775A5067101373 @default.
- W4254774775 hasBestOaLocation W42547747751 @default.
- W4254774775 hasConcept C142724271 @default.
- W4254774775 hasConcept C153911025 @default.
- W4254774775 hasConcept C159654299 @default.
- W4254774775 hasConcept C185592680 @default.
- W4254774775 hasConcept C190283241 @default.
- W4254774775 hasConcept C202751555 @default.
- W4254774775 hasConcept C203014093 @default.
- W4254774775 hasConcept C204232928 @default.
- W4254774775 hasConcept C2776146153 @default.
- W4254774775 hasConcept C2777407522 @default.
- W4254774775 hasConcept C2777807558 @default.
- W4254774775 hasConcept C2909316934 @default.
- W4254774775 hasConcept C502942594 @default.
- W4254774775 hasConcept C542903549 @default.
- W4254774775 hasConcept C55493867 @default.
- W4254774775 hasConcept C71924100 @default.
- W4254774775 hasConcept C86803240 @default.
- W4254774775 hasConceptScore W4254774775C142724271 @default.
- W4254774775 hasConceptScore W4254774775C153911025 @default.
- W4254774775 hasConceptScore W4254774775C159654299 @default.
- W4254774775 hasConceptScore W4254774775C185592680 @default.
- W4254774775 hasConceptScore W4254774775C190283241 @default.
- W4254774775 hasConceptScore W4254774775C202751555 @default.
- W4254774775 hasConceptScore W4254774775C203014093 @default.
- W4254774775 hasConceptScore W4254774775C204232928 @default.
- W4254774775 hasConceptScore W4254774775C2776146153 @default.
- W4254774775 hasConceptScore W4254774775C2777407522 @default.
- W4254774775 hasConceptScore W4254774775C2777807558 @default.
- W4254774775 hasConceptScore W4254774775C2909316934 @default.
- W4254774775 hasConceptScore W4254774775C502942594 @default.
- W4254774775 hasConceptScore W4254774775C542903549 @default.
- W4254774775 hasConceptScore W4254774775C55493867 @default.
- W4254774775 hasConceptScore W4254774775C71924100 @default.
- W4254774775 hasConceptScore W4254774775C86803240 @default.
- W4254774775 hasLocation W42547747751 @default.
- W4254774775 hasOpenAccess W4254774775 @default.
- W4254774775 hasPrimaryLocation W42547747751 @default.
- W4254774775 hasRelatedWork W1858303686 @default.
- W4254774775 hasRelatedWork W1971628265 @default.
- W4254774775 hasRelatedWork W1973774944 @default.
- W4254774775 hasRelatedWork W1985628011 @default.
- W4254774775 hasRelatedWork W2027565419 @default.
- W4254774775 hasRelatedWork W2091601748 @default.
- W4254774775 hasRelatedWork W2168323396 @default.
- W4254774775 hasRelatedWork W2465136625 @default.
- W4254774775 hasRelatedWork W3193697446 @default.
- W4254774775 hasRelatedWork W4254774775 @default.
- W4254774775 isParatext "false" @default.
- W4254774775 isRetracted "false" @default.
- W4254774775 workType "article" @default.